Informations générales (source: ClinicalTrials.gov)
Analysis of Volatile Organic Compounds in the Exhaled Air Breath of in Bilateral Lung Transplant Recipients Bi-pulmonary Transplant Patients: Search for Acute Rejection Markers
Interventional
N/A
Hopital Foch (Voir sur ClinicalTrials)
juin 2017
octobre 2021
18 septembre 2025
The aim of research is to identify markers of acute rejection by VOC analysis in exhaled
breath of bilateral-lung transplanted patients. 120 bi-lung transplanted patients will be
divided into two groups : patients with acute rejection diagnosed on transbronchial
biopsies and patients with no acute rejection. Exhaled breath will be collected for VOC
analysis woth electronic nose and mass spectrometry. VOC profiles will be compared
between the two groups of patients.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FOCH | Antoine Roux | vendredi 11 mars 2022 | Contact (sur clinicalTrials) | ||
Critères
Tous
Inclusion Criteria:
- Bi-pulmonary transplant patient
- Acute rejection group: Patients with transbronchial biopsies performed as part of
their usual follow-up or for functional abnormality ; Diagnosis of acute rejection
retained on the following arguments: histological lesions of cellular rejection or
histological lesions of humoral rejection or normal histology but diagnosis of
"functional rejection" retained and immunosuppressive treatment indicated
- Control group: Patients benefiting from systematically programmed transbronchial
biopsies as part of post-transplant follow-up with normal histology and absence of
functional respiratory abnormality
- Bi-pulmonary transplant patient
- Acute rejection group: Patients with transbronchial biopsies performed as part of
their usual follow-up or for functional abnormality ; Diagnosis of acute rejection
retained on the following arguments: histological lesions of cellular rejection or
histological lesions of humoral rejection or normal histology but diagnosis of
"functional rejection" retained and immunosuppressive treatment indicated
- Control group: Patients benefiting from systematically programmed transbronchial
biopsies as part of post-transplant follow-up with normal histology and absence of
functional respiratory abnormality
- Patient unable to realize a vital capacity measure
- Neoplasia currently treated
- Unresolved acute bronchial complication (stenosis or dehiscence)
- Immunosuppressive treatment of acute rejection already begun
- Patient who has already participated in the protocol and already included in one of
the two study groups